According to Johnson & Johnson, this approval marks the first multi-targeted therapy to surpass Tagrisso in efficacy in first-line treatment of advanced non-small cell lung cancer.
FDA approves Johnson & Johnson’s Rybrevant and Lazcluze for advanced non-small cell lung cancer
Leave a comment
